Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Treatment of Women With Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin
Sponsor: Genentech, Inc.
This PHASE1 trial investigates Fallopian Tube Cancer and Ovarian Cancer and is currently ongoing. Genentech, Inc. leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Oct 2018 — Sep 2020 [monthly]
Active Not Recruiting PHASE1
Phase: NA → PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting NA
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Massachusetts General Hospital
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .